Drug Combination Details
| General Information of the Combination (ID: C65360) | |||||
|---|---|---|---|---|---|
| Name | Heparin NP Info | + | Bivalirudin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Myocardial infarction
[ICD-11: BA41]
|
Phase 4 | [1] | ||
|
Thrombosis
[ICD-11: DB61-GB90]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Biological
Regulation |
Decrease | clotting time | ||||
| In-vitro Model | Human fibroblasts collected from a skin biopsy | Healthy | Homo sapiens | |||
| Human liver non-parenchymal cells obtained after liver isolation | Healthy | Homo sapiens | ||||
| hALPCs obtained from healthy liver donors | Healthy | Homo sapiens | ||||
| Experimental
Result(s) |
Concomitant administration of an antithrombin activator or direct factor Xa inhibitor and direct thrombin inhibitor proved to be a particularly effective combination for controlling the procoagulant effects of hALPCs both in vitro and in vivo. | |||||
